Did You Know Q2 2019
By Brian Koffman, MD
- Despite the importance of doing predictive testing before treatment, research presented at ASH 2018 showed fewer doctors are doing the recommended tests compared to when the frequency of testing was last studied.
- CAR-T cell immune therapy, although still experimental for CLL, was named by ASCO (American Society of Clinical Oncology) as “The 2018 Advance of the Year”.
- Some patients with low-risk CLL have the same life expectancy as matched controls without CLL.
Dr. Brian Koffman, a well-known doctor, educator, and clinical professor turned patient has dedicated himself to teaching and helping the CLL community since his diagnosis in 2005. He serves as the Executive Vice President and Chief Medical Officer of the CLL Society Inc.
Originally published in The CLL Tribune Q4 2018.
Related posts